Survival analysis considering all patients with breast cancer did not evidence differences but we found correlations between TUG1 expression and overall-survival in patients classified as luminal B or HER2-enriched: patients with the lowest TUG1 expression had lower survival in luminal B patients, while the highest TUG1 expression was associated with poor overall survival in HER2-enriched patients. Here, ERBB2 is linked to breast carcinoma.